Danica Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danica Dong has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- David J. Dowling
Precision Vaccines Program, Boston Children’s Hospital, Boston, MA, USA
3 shared publications Francesco Borriello
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
3 shared publications- Hyuk-Soo Seo
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
3 shared publications - Ofer Levy
Precision Vaccines Program, Boston Children’s Hospital, Harvard Medical School, Boston, USA
3 shared publications - Soumik Barman
Precision Vaccines Program, Boston Children’s Hospital, Boston, MA, USA
3 shared publications - Timothy R. O'MEara
Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA
3 shared publications
Latest Publications
- 31 August 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (11) , 1652-1656
Extended Support With an Impella 5.5: Single‐Center Experience and Outcomes
Background: Prolonged use of the Impella 5.5 is becoming increasingly common in patients requiring temporary mechanical circulatory support, yet its association with mortality and neurologic outcomes remains uncertain. We evaluated whether prolonged Impella 5.5 support was independently associated with adverse clinical outcomes at a tertiary center. Methods: We retrospectively studied adults who underwent Impella 5.5 implantation between January 2022 and December 2025. Patients receiving intraoperative support or concomitant extracorporeal membrane oxygenation with Impella were excluded. Prolonged support was defined as duration exceeding the third quartile (> 27 days). The primary outcome was in‐hospital mortality. The secondary outcome was unfavorable neurologic outcome at discharge, defined as modified Rankin Scale > 0, with death assigned a score of 6. Multivariable logistic regression adjusted for body mass index (BMI) and Charlson Comorbidity Index (CCI). Results: Among 129 patients (median age 61 years, 74.4% male), median support duration was 15 days. Overall, in‐hospital mortality was 21.7%, and unfavorable neurologic outcome occurred in 36.5% of patients. Patients requiring prolonged support had greater comorbidity burden (CCI 3 vs. 2, p = 0.007) and longer intensive care unit (55.59 vs. 25.47 days, p < 0.001) and hospital (78.5 vs. 44.0 days, p < 0.001) stays. However, prolonged support was not independently associated with in‐hospital mortality (aOR: 2.16, 95% CI: 0.69–6.54, p = 0.174) or unfavorable neurologic outcome (aOR: 1.58, 95% CI: 0.64–3.90, p = 0.321). Conclusions: Prolonged Impella 5.5 support was associated with greater resource utilization but was not significantly associated with adjusted mortality or adverse neurologic outcomes in this cohort.
- 31 August 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (11) , 1652-1656
Extended Support With an Impella 5.5: Single‐Center Experience and Outcomes
Background: Prolonged use of the Impella 5.5 is becoming increasingly common in patients requiring temporary mechanical circulatory support, yet its association with mortality and neurologic outcomes remains uncertain. We evaluated whether prolonged Impella 5.5 support was independently associated with adverse clinical outcomes at a tertiary center. Methods: We retrospectively studied adults who underwent Impella 5.5 implantation between January 2022 and December 2025. Patients receiving intraoperative support or concomitant extracorporeal membrane oxygenation with Impella were excluded. Prolonged support was defined as duration exceeding the third quartile (> 27 days). The primary outcome was in‐hospital mortality. The secondary outcome was unfavorable neurologic outcome at discharge, defined as modified Rankin Scale > 0, with death assigned a score of 6. Multivariable logistic regression adjusted for body mass index (BMI) and Charlson Comorbidity Index (CCI). Results: Among 129 patients (median age 61 years, 74.4% male), median support duration was 15 days. Overall, in‐hospital mortality was 21.7%, and unfavorable neurologic outcome occurred in 36.5% of patients. Patients requiring prolonged support had greater comorbidity burden (CCI 3 vs. 2, p = 0.007) and longer intensive care unit (55.59 vs. 25.47 days, p < 0.001) and hospital (78.5 vs. 44.0 days, p < 0.001) stays. However, prolonged support was not independently associated with in‐hospital mortality (aOR: 2.16, 95% CI: 0.69–6.54, p = 0.174) or unfavorable neurologic outcome (aOR: 1.58, 95% CI: 0.64–3.90, p = 0.321). Conclusions: Prolonged Impella 5.5 support was associated with greater resource utilization but was not significantly associated with adjusted mortality or adverse neurologic outcomes in this cohort.
- Open Access
- 4 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Discovery of a small molecule TLR3 agonist adjuvant
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.
- 4 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDiscovery of a small molecule TLR3 agonist adjuvant
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.
- Open Access
- 3 March 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1
Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
- 3 March 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1
Open AccessPublisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
- Open Access
- 14 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-16
Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses. Comparison of multiple adjuvants including AddaVax, AddaS03, and AS01B in young and aged mice demonstrated that an oil-in-water emulsion containing carbohydrate fatty acid monosulphate derivative (CMS:O/W) most effectively enhanced RBD-NP-induced cross-neutralizing antibodies and protection across age groups. CMS:O/W enhanced antigen retention in the draining lymph node, induced injection site, and lymph node cytokines, with CMS inducing MyD88-dependent Th1 cytokine polarization. Furthermore, CMS and O/W synergistically induced chemokine production from human PBMCs. Overall, CMS:O/W adjuvant may enhance immunogenicity and protection of vulnerable populations against SARS-CoV-2 and other infectious pathogens.
- 14 February 2023
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-16
Open AccessCarbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice
Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses. Comparison of multiple adjuvants including AddaVax, AddaS03, and AS01B in young and aged mice demonstrated that an oil-in-water emulsion containing carbohydrate fatty acid monosulphate derivative (CMS:O/W) most effectively enhanced RBD-NP-induced cross-neutralizing antibodies and protection across age groups. CMS:O/W enhanced antigen retention in the draining lymph node, induced injection site, and lymph node cytokines, with CMS inducing MyD88-dependent Th1 cytokine polarization. Furthermore, CMS and O/W synergistically induced chemokine production from human PBMCs. Overall, CMS:O/W adjuvant may enhance immunogenicity and protection of vulnerable populations against SARS-CoV-2 and other infectious pathogens.